$15.85 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Pulmonx

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Stock Analysis

last close $15.85
1-mo return -14.9%
3-mo return -34.9%
avg daily vol. 683.98T
52-week high 45.81
52-week low 13.84
market cap. $532M
forward pe -
annual div. -
roe -26.3%
ltg forecast 23.6%
dividend yield -
annual rev. $50M
inst own. -

Subscribe now for daily local and international financial news